 |
November 30, 2004, Orlando Florida.
SurgiLight,
Inc. (SRGL.OB) has just received an allowance notice
for its U.S. Patent entitled “Apparatus and Methods
for the Treatment of Presbyopia Using Fiber-Coupled Lasers.”
This method patent discussed a means for correcting Presbyopia
by removing a portion of the sclera to a specific depth with
a focused beam delivered by a fiber. The patent cites both
infrared and ultraviolet laser wavelengths.
With the
issuance of this patent, SurgiLight now owns four U.S. patents
on Presbyopia and has 15 pending applications worldwide. In
addition, SurgiLight owns 4 patents and 9 patent applications
and holds an exclusive license on another 10 patents or patent
applications. These patents cover the laser device, delivery
system and certain methods and were acquired from Premier
Laser Systems.
Dr. Cozean,
CEO and Chairwoman of SurgiLight, Inc., reported that “SurgiLight
was pleased with this recognition by the U.S. Patent Office,
that SurgiLight is the leader is laser correction of Presbyopia.
It is important to recognize,” she continued, “that
the SurgiLight Laser Presbyopia Reveral Procedure (LAPR) actually
restores accommodation without an implant or without resorting
to monovision where one eye is corrected for near vision and
one eye for distance vision.”
This media release may contain
forward-looking statements regarding but not limited to market
potential, distributor success, market size, international
approvals, FDA clearances, clinical studies and results of
those studies, marketing, future events and performance of
SurgiLight, which involve risks and uncertainties that could
materially affect actual results. Investors should refer to
documents that SurgiLight files with the SEC for a description
of certain factors that could cause actual results to vary
from current expectations and the forward-looking statements
contained in this media release.
Keywords:
surgilight, surgilight.com, SurgiLight, SurgiLight Inc.,Surgi
Light, OptiVision, presbyopia, laser presbyopia reversal,
LAPR, refractive surgery, accomodation, ophthalmology, new
trends in ophthalmology, laser, ophthalmology laster, erbium
yag, YAG, glaucoma.
|
|
|
Disclaimer:
All material herein is information supplied by the company or
other sources believed to be reliable. The information contained
herein is not guaranteed by TheNewsGate.com to be accurate,
and should not be considered to be all-inclusive. The companies
that are discussed in this profile have approved the statements
made in this profile. This profile contains forward-looking
statements that involve risks and uncertainties. Statements
in this press release about the company's future expectations,
including: development of licensing and branding and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of
section 27A of the Securities Act of 1933, section 21E of the
Securities Act of 1934, as that term is defined in the Private
Securities Reform Act of 1995. It is important to note that
actual results and ultimate corporate actions could differ materially
from those in such forward looking statements. Such "forward-looking
statements" are subject to risks and uncertainties set
forth from time to time in the Company's SEC reports. This material
is for informational purposes only and should not be construed
as an offer or solicitation of an offer to buy or sell securities.
TheNewsGate.com is not a licensed broker, broker dealer, market
marker, investment advisor, analyst or underwriter. Please consult
a broker before purchasing or selling any securities viewed
on http://TheNewsGate.com/ TheNewsGate.com's affiliates, officers,
directors and employees may have bought or may buy the shares
discussed in this profile and may profit in the event those
shares rise in value. TheNewsGate.com does not and will not
offer any opinion as to when others should sell; each investor
must make that decision based on his or her judgment of the
market.
|
|
